Tonghua Dongbao Pharmaceutical Co Ltd Total Assets
Tonghua Dongbao Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) holds total assets worth CN¥8.25 Billion CNY (≈ $1.21 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tonghua Dongbao Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Tonghua Dongbao Pharmaceutical Co Ltd (1994–2025)
Total assets of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2025. This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Tonghua Dongbao Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Tonghua Dongbao Pharmaceutical Co Ltd - Asset Composition Analysis
Tonghua Dongbao Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Tonghua Dongbao Pharmaceutical Co Ltd total assets breakdown as of December 2025. Tonghua Dongbao Pharmaceutical Co Ltd's total assets of CN¥8.25 Billion consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.1% |
| Accounts Receivable | CN¥409.02 Million | 5.2% |
| Inventory | CN¥704.22 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.64 Billion | 20.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 600867 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tonghua Dongbao Pharmaceutical Co Ltd's current assets represent 34.7% of total assets in 2025, a decrease from 77.1% in 1994.
- Cash Position: Cash and equivalents constituted 18.1% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 20.8% of total assets.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Tonghua Dongbao Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Tonghua Dongbao Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.84 | 2.89 | 7.50 |
| Quick Ratio | 3.85 | 1.85 | 5.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.43 Billion | CN¥1.37 Billion | CN¥1.78 Billion |
Tonghua Dongbao Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tonghua Dongbao Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.03 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 7.2% |
| Total Assets | CN¥7.91 Billion |
| Market Capitalization | $2.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tonghua Dongbao Pharmaceutical Co Ltd's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tonghua Dongbao Pharmaceutical Co Ltd's assets grew by 7.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tonghua Dongbao Pharmaceutical Co Ltd (1994–2025)
The table below shows the annual total assets of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.91 Billion ≈ $1.16 Billion |
+7.15% |
| 2024-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
-5.06% |
| 2023-12-31 | CN¥7.77 Billion ≈ $1.14 Billion |
+15.13% |
| 2022-12-31 | CN¥6.75 Billion ≈ $987.78 Million |
+3.53% |
| 2021-12-31 | CN¥6.52 Billion ≈ $954.10 Million |
+12.35% |
| 2020-12-31 | CN¥5.80 Billion ≈ $849.20 Million |
+8.47% |
| 2019-12-31 | CN¥5.35 Billion ≈ $782.86 Million |
-2.08% |
| 2018-12-31 | CN¥5.46 Billion ≈ $799.46 Million |
+14.95% |
| 2017-12-31 | CN¥4.75 Billion ≈ $695.47 Million |
+1.66% |
| 2016-12-31 | CN¥4.68 Billion ≈ $684.10 Million |
+23.41% |
| 2015-12-31 | CN¥3.79 Billion ≈ $554.32 Million |
+28.14% |
| 2014-12-31 | CN¥2.96 Billion ≈ $432.59 Million |
+9.72% |
| 2013-12-31 | CN¥2.69 Billion ≈ $394.28 Million |
+13.21% |
| 2012-12-31 | CN¥2.38 Billion ≈ $348.29 Million |
+0.12% |
| 2011-12-31 | CN¥2.38 Billion ≈ $347.88 Million |
+8.74% |
| 2010-12-31 | CN¥2.19 Billion ≈ $319.93 Million |
-2.89% |
| 2009-12-31 | CN¥2.25 Billion ≈ $329.46 Million |
+3.69% |
| 2008-12-31 | CN¥2.17 Billion ≈ $317.73 Million |
-4.31% |
| 2007-12-31 | CN¥2.27 Billion ≈ $332.02 Million |
+15.35% |
| 2006-12-31 | CN¥1.97 Billion ≈ $287.85 Million |
+4.36% |
| 2005-12-31 | CN¥1.88 Billion ≈ $275.83 Million |
+4.36% |
| 2004-12-31 | CN¥1.81 Billion ≈ $264.31 Million |
+0.62% |
| 2003-12-31 | CN¥1.80 Billion ≈ $262.68 Million |
+14.45% |
| 2002-12-31 | CN¥1.57 Billion ≈ $229.53 Million |
+7.69% |
| 2001-12-31 | CN¥1.46 Billion ≈ $213.13 Million |
-0.86% |
| 2000-12-31 | CN¥1.47 Billion ≈ $214.98 Million |
-1.89% |
| 1999-12-31 | CN¥1.50 Billion ≈ $219.12 Million |
+27.04% |
| 1998-12-31 | CN¥1.18 Billion ≈ $172.48 Million |
+34.71% |
| 1997-12-31 | CN¥875.03 Million ≈ $128.04 Million |
+76.45% |
| 1996-12-31 | CN¥495.92 Million ≈ $72.57 Million |
+51.44% |
| 1995-12-31 | CN¥327.48 Million ≈ $47.92 Million |
+22.87% |
| 1994-12-31 | CN¥266.52 Million ≈ $39.00 Million |
-- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more